BioPharma Dive January 21, 2025
Sionna aims to challenge Vertex in cystic fibrosis, while Odyssey is developing targeted medicines for autoimmune conditions.
Dive Brief:
- Two biotechnology startups on Friday revealed plans to launch initial public offerings, extending a step-up in IPO activity among privately held drug companies.
- Sionna Therapeutics is working on therapies for cystic fibrosis, several of which are in early-stage testing. Odyssey Therapeutics aims to tap Wall Street to develop targeted drugs for immune diseases, the most advanced of which could begin a Phase 2 trial in ulcerative colitis this quarter.
- Sionna and Odyssey are the fourth and fifth biotech companies to file for IPOs since late December. Over the last three years, however, bursts of IPO activity have typically been followed...
Today's Sponsors
Today's Sponsor